Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?

被引：0
|
作者：
Avasarala, Jagannadha [1 ]
机构：
[1] Univ Kentucky Med Ctr, Dept Neurol, 740 S Limestone, Lexington, KY 40536 USA
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2024年 / 90卷 / 12期
关键词：
Anti-CD20; drugs; B cell repopulation; CD19 cell counts; COVID; 19; susceptibility; dosing frequency; multiple sclerosis; vaccine response; DEPLETION;
D O I：
10.1111/bcp.16248
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：3094 / 3096
页数：3
相关论文
共 50 条
  • [31] Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?
    Moghadasi, Abdorreza Naser
    Shabany, Maryam
    Heidari, Hora
    Eskandarieh, Sharareh
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2021, 203
  • [32] Blunted Post-COVID-19 Humoral Immunity in Patients With CNS Demyelinating Disorders on Anti-CD20 Treatments
    Money, Kelli M.
    Baber, Ursela
    Saart, Emma
    Samaan, Soleil
    Sloane, Jacob A.
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [33] Neutropenia complicating anti-CD20 treatment in patients with multiple sclerosis: A retrospective case series and a systematic review of reported cases
    Rossi, Lucrezia
    Dinoto, Alessandro
    Bratina, Alessio
    Baldini, Sara
    Pasquin, Fulvio
    Bosco, Antonio
    Sartori, Arianna
    Manganotti, Paolo
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [34] COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues
    Chirap-Mitulschi, Ioan-Alexandru
    Ghimus, Constantin
    Chirap-Mitulschi, Andreea Raluca
    Antoniu, Sabina Antonela
    Dragomir, Raluca
    DRUGS OF TODAY, 2022, 58 (12) : 605 - 620
  • [35] Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination
    Golshani, Maryam
    Hrdy, Jiri
    VACCINES, 2022, 10 (02)
  • [36] Efficacy of Accelerated Vaccination against Hbv to Achieve Antibody formation in Multiple Sclerosis Patients Receiving Anti-Cd20 Therapy
    Koc, Emine Rabia
    Turan, Omer Faruk
    Saridas, Furkan
    Menguc, Bedirhan
    Minaz, Sema Nur
    Ozkaya, Guven
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2023, 26 (05) : 697 - 701
  • [37] Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Achiron, Anat
    Mandel, Mathilda
    Dreyer-Alster, Sapir
    Harari, Gil
    Magalashvili, David
    Sonis, Polina
    Dolev, Mark
    Menascu, Shay
    Flechter, Shlomo
    Falb, Rina
    Gurevich, Michael
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [38] Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study
    Fernandes, Andre Aires
    Neves, Ana Lidia
    Ferro, Daniela
    Seabra, Mafalda
    Mendonca, Teresa
    dos Reis, Ricardo Soares
    Sa, Maria Jose
    Guimaraes, Joana
    Abreu, Pedro
    FRONTIERS IN NEUROLOGY, 2025, 15
  • [39] Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy
    Nuray Bilge
    Fatma Kesmez Can
    Recep Yevgi
    Acta Neurologica Belgica, 2023, 123 : 1885 - 1892
  • [40] Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies
    Baba, Cavid
    Ozcelik, Sinem
    Kaya, Ergi
    Samedzada, Ulvi
    Ozdogar, Asiye Tuba
    Cevik, Sumeyye
    Dogan, Yavuz
    Ozakbas, Serkan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
12345